BioMarin: A Rare Disease Specialist With An Eye On The Long-Term
This article was originally published in The Pink Sheet Daily
Executive Summary
BioMarin is in the midst of a pivotal year, with several near-term data catalysts, the most important of which will be Phase III data on GALNS for the rare disease MPS IV.